Hosted on MSN1mon
Olix, Eli Lilly to develop liver disease drug under $630 million deal
Olix Pharmaceuticals signed a $630 million licensing deal with Eli Lilly and Company to develop and commercialize treatments targeting cardiovascular and metabolic diseases. Olix will grant Eli ...
FierceBiotech1mon
Eli Lilly inks duo of deals, teaming with AdvanCell, OliX to push deeper into radiopharma, MASH
Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big Pharma is coughing up cash to work with them on radiopharmaceuticals ...
Nature1y
Developing RNAi therapeutics targeting hepatic and extra-hepatic diseases
Overcoming these problems with its unique gene-silencing technology is OliX Pharmaceuticals, a clinical-stage/pure-play RNAi-therapeutics company that is changing the paradigm of RNAi-therapeutic ...
AOL1mon
Eli Lilly Seeks To Expand Into Cancer Radiopharma And Fatty Liver, With Two Global Deals
Financial terms of the agreement were not disclosed. Concurrently, Korea-based OliX Pharmaceuticals Inc. announced a global licensing agreement with Eli Lilly for the development and ...
PMLiVE29d
Eli Lilly and OliX partner to advance early-stage metabolic disease candidate
Eli Lilly and RNAi therapeutics specialist OliX Pharmaceuticals have entered into a global licensing agreement to advance a phase 1 candidate for metabolic-associated steatohepatitis (MASH) and other ...
Nature4y
Driving drug development through next-generation oligonucleotide technology
OliX Pharmaceuticals, the first Asian company to advance its own proprietary RNA interference (RNAi) technology platform into the clinic, is using RNAi technology to treat skin, eye and lung ...